Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025BloodOpen Access

Development of novel MZB1-directed HLA-dependent CAR T cell and CAR enhancer therapy in MM and other B-cell malignancies

View Full Paper
Ask AI
Bookmark
Share

Authors

EME MartinMHMengdong HeSKSara Mangesh Kolhatkar

Discussion

Loading...

Member takes

Overview

This work demonstrates enhanced cytotoxicity of MZB1 CAR T cells in Waldenström Macroglobulinemia, indicating a novel therapeutic path.

Key Points

  • MZB1 CAR T cells showed significant cytotoxicity against multiple myeloma cells, improving treatment options.
  • In vitro assays revealed MZB1 CAR T cells secreted higher granzyme A/B and demonstrated enhanced activity.
  • This research highlights clinical application of MZB1-directed CAR T cells for better cancer targeting.
  • Findings suggest that CAR enhancer treatment may further improve T cell persistence and antitumor efficacy.

Cite This Study

Martin et al. (2025) studied this question.

synapsesocial.com/papers/69362f764fa91c937236e3f3https://doi.org/10.1182/blood-2025-2332
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Innovative sdab-based CAR-T cells targeting BCMA outperform current CAR-T therapies for multiple myeloma2025
  2. 2Preclinical development of an optimized manufacturing, CRISPR-edited, fully non-viral 1XX-enhanced anti-BCMA CAR-T therapy for multiple myeloma2025
  3. 3[Next-generation CAR gene-modified cell therapy: overcoming resistance and exploring novel applications].2025
  4. 4Balancing efficacy and safety: IL-15 BCMA CAR-T cells vs. 2nd generation CAR-T in preclinical myeloma model2025
  5. 5Data from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited2025